In a new Medtech innovation briefing, National Institute for Health and Care Excellence has recommended Leukomed Sorbact for preventing surgical site infection (SSI).
Leukomed Sorbact, a sterile, single-use, bacteria-binding, wound dressing is recommended for the prevention of SSI in closed surgical incisions with up to moderate exudate levels.
The innovative dressing comprises an absorbent non-woven wound contact pad and an adhesive polyurethane film. The pad is made of white viscose polypropylene and polyester laminated to the dialkylcarbamoyl chloride (DACC)-coated Sorbact mesh. DACC is hydrophobic in nature and thus physically binds to SSI-causing hydrophobic microorganisms and moves them away from the wound surface towards the dressing.
Current standard care for preventing SSI includes covering surgical incisions with an appropriate interactive dressing and changing or removal of dressings using aseptic non-touch technique. Evidence from four clinical trials (three randomised and one non-randomised) suggests Leukomed Sorbact could have better efficacy than standard post-surgical dressings in the prevention of SSI in closed surgical wounds of caesarean section and vascular surgery.